390 related articles for article (PubMed ID: 34314483)
21. Extravascular hemolysis and complement consumption in Paroxysmal Nocturnal Hemoglobinuria patients undergoing eculizumab treatment.
Subías Hidalgo M; Martin Merinero H; López A; Anter J; García SP; Ataúlfo Gonzalez-Fernández F; Forés R; Lopez-Trascasa M; Villegas A; Ojeda E; Rodríguez de Córdoba S
Immunobiology; 2017 Feb; 222(2):363-371. PubMed ID: 27644115
[TBL] [Abstract][Full Text] [Related]
22. Predictors for improvement in patient-reported outcomes: post hoc analysis of a phase 3 randomized, open-label study of eculizumab and ravulizumab in complement inhibitor-naive patients with paroxysmal nocturnal hemoglobinuria.
Schrezenmeier H; Kulasekararaj A; Mitchell L; de Latour RP; Devos T; Okamoto S; Wells R; Popoff E; Cheung A; Wang A; Tomazos I; Patel Y; Lee JW
Ann Hematol; 2024 Jan; 103(1):5-15. PubMed ID: 37804344
[TBL] [Abstract][Full Text] [Related]
23. Safety of current treatments for paroxysmal nocturnal hemoglobinuria.
Lee SE; Lee JW
Expert Opin Drug Saf; 2021 Feb; 20(2):171-179. PubMed ID: 33249943
[No Abstract] [Full Text] [Related]
24. Phase 3 Study of Subcutaneous Versus Intravenous Ravulizumab in Eculizumab-Experienced Adult Patients with PNH: Primary Analysis and 1-Year Follow-Up.
Yenerel MN; Sicre de Fontbrune F; Piatek C; Sahin F; Füreder W; Ortiz S; Ogawa M; Ozol-Godfrey A; Sierra JR; Szer J
Adv Ther; 2023 Jan; 40(1):211-232. PubMed ID: 36272026
[TBL] [Abstract][Full Text] [Related]
25. Pegcetacoplan: A Review in Paroxysmal Nocturnal Haemoglobinuria.
Heo YA
Drugs; 2022 Dec; 82(18):1727-1735. PubMed ID: 36459381
[TBL] [Abstract][Full Text] [Related]
26. Eculizumab for treating patients with paroxysmal nocturnal hemoglobinuria.
Martí-Carvajal AJ; Anand V; Cardona AF; Solà I
Cochrane Database Syst Rev; 2014 Oct; (10):CD010340. PubMed ID: 25356860
[TBL] [Abstract][Full Text] [Related]
27. Achievements and limitations of complement inhibition by eculizumab in paroxysmal nocturnal hemoglobinuria: the role of complement component 3.
Risitano AM; Perna F; Selleri C
Mini Rev Med Chem; 2011 Jun; 11(6):528-35. PubMed ID: 21561403
[TBL] [Abstract][Full Text] [Related]
28. Safety and Efficacy of Pegcetacoplan in Adult Patients with Paroxysmal Nocturnal Hemoglobinuria over 48 Weeks: 307 Open-Label Extension Study.
Patriquin CJ; Bogdanovic A; Griffin M; Kelly RJ; Maciejewski JP; Mulherin B; Peffault de Latour R; Röth A; Selvaratnam V; Szer J; Al-Adhami M; Horneff R; Tan L; Yeh M; Panse J
Adv Ther; 2024 May; 41(5):2050-2069. PubMed ID: 38573482
[TBL] [Abstract][Full Text] [Related]
29. Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria.
Hillmen P; Hall C; Marsh JC; Elebute M; Bombara MP; Petro BE; Cullen MJ; Richards SJ; Rollins SA; Mojcik CF; Rother RP
N Engl J Med; 2004 Feb; 350(6):552-9. PubMed ID: 14762182
[TBL] [Abstract][Full Text] [Related]
30. Hemolysis events in the phase 3 PEGASUS study of pegcetacoplan in patients with paroxysmal nocturnal hemoglobinuria.
Peffault de Latour R; Griffin M; Kelly RJ; Szer J; de Castro C; Horneff R; Tan L; Yeh M; Panse J
Blood Adv; 2024 Jun; 8(11):2718-2725. PubMed ID: 38593241
[TBL] [Abstract][Full Text] [Related]
31. Cost burden of breakthrough hemolysis in patients with paroxysmal nocturnal hemoglobinuria receiving ravulizumab versus eculizumab.
Tomazos I; Sierra JR; Johnston KM; Cheung A; Brodsky RA; Weitz IC
Hematology; 2020 Dec; 25(1):327-334. PubMed ID: 32856539
[No Abstract] [Full Text] [Related]
32. C3 inhibition with pegcetacoplan in subjects with paroxysmal nocturnal hemoglobinuria treated with eculizumab.
de Castro C; Grossi F; Weitz IC; Maciejewski J; Sharma V; Roman E; Brodsky RA; Tan L; Di Casoli C; El Mehdi D; Deschatelets P; Francois C
Am J Hematol; 2020 Nov; 95(11):1334-1343. PubMed ID: 33464651
[TBL] [Abstract][Full Text] [Related]
33. Pegcetacoplan controls hemolysis in complement inhibitor-naive patients with paroxysmal nocturnal hemoglobinuria.
Wong RSM; Navarro-Cabrera JR; Comia NS; Goh YT; Idrobo H; Kongkabpan D; Gómez-Almaguer D; Al-Adhami M; Ajayi T; Alvarenga P; Savage J; Deschatelets P; Francois C; Grossi F; Dumagay T
Blood Adv; 2023 Jun; 7(11):2468-2478. PubMed ID: 36848639
[TBL] [Abstract][Full Text] [Related]
34. Oral Iptacopan Monotherapy in Paroxysmal Nocturnal Hemoglobinuria.
Peffault de Latour R; Röth A; Kulasekararaj AG; Han B; Scheinberg P; Maciejewski JP; Ueda Y; de Castro CM; Di Bona E; Fu R; Zhang L; Griffin M; Langemeijer SMC; Panse J; Schrezenmeier H; Barcellini W; Mauad VAQ; Schafhausen P; Tavitian S; Beggiato E; Chew LP; Gaya A; Huang WH; Jang JH; Kitawaki T; Kutlar A; Notaro R; Pullarkat V; Schubert J; Terriou L; Uchiyama M; Wong Lee Lee L; Yap ES; Sicre de Fontbrune F; Marano L; Alashkar F; Gandhi S; Trikha R; Yang C; Liu H; Kelly RJ; Höchsmann B; Kerloeguen C; Banerjee P; Levitch R; Kumar R; Wang Z; Thorburn C; Maitra S; Li S; Verles A; Dahlke M; Risitano AM
N Engl J Med; 2024 Mar; 390(11):994-1008. PubMed ID: 38477987
[TBL] [Abstract][Full Text] [Related]
35. Safety and efficacy of the terminal complement inhibitor eculizumab in Japanese patients with paroxysmal nocturnal hemoglobinuria: the AEGIS clinical trial.
Kanakura Y; Ohyashiki K; Shichishima T; Okamoto S; Ando K; Ninomiya H; Kawaguchi T; Nakao S; Nakakuma H; Nishimura J; Kinoshita T; Bedrosian CL; Valentine ME; Khursigara G; Ozawa K; Omine M
Int J Hematol; 2011 Jan; 93(1):36-46. PubMed ID: 21222185
[TBL] [Abstract][Full Text] [Related]
36. Clinical benefit of eculizumab in patients with no transfusion history in the International Paroxysmal Nocturnal Haemoglobinuria Registry.
Almeida AM; Bedrosian C; Cole A; Muus P; Schrezenmeier H; Szer J; Rosse WF
Intern Med J; 2017 Sep; 47(9):1026-1034. PubMed ID: 28608499
[TBL] [Abstract][Full Text] [Related]
37. Complement Inhibitors in the Management of Complement-Mediated Hemolytic Uremic Syndrome and Paroxysmal Nocturnal Hemoglobinuria.
Begum F; Khan N; Boisclair S; Malieckal DA; Chitty D
Am J Ther; 2023 May; 30(3):e209-e219. PubMed ID: 37104648
[TBL] [Abstract][Full Text] [Related]
38. Beneficial effects of eculizumab regardless of prior transfusions or bone marrow disease: Results of the International Paroxysmal Nocturnal Hemoglobinuria Registry.
Röth A; Araten DJ; Larratt L; Kulasekararaj AG; Maciejewski JP; Wilson A; Gustovic P; Kanakura Y
Eur J Haematol; 2020 Nov; 105(5):561-570. PubMed ID: 32640047
[TBL] [Abstract][Full Text] [Related]
39. Patient preferences and quality of life implications of ravulizumab (every 8 weeks) and eculizumab (every 2 weeks) for the treatment of paroxysmal nocturnal hemoglobinuria.
Peipert JD; Kulasekararaj AG; Gaya A; Langemeijer SMC; Yount S; Gonzalez-Fernandez FA; Ojeda Gutierrez E; Martens C; Sparling A; Webster KA; Cella D; Tomazos I; Ogawa M; Piatek CI; Wells R; Sicre de Fontbrune F; Röth A; Mitchell L; Hill A; Kaiser K
PLoS One; 2020; 15(9):e0237497. PubMed ID: 32886668
[TBL] [Abstract][Full Text] [Related]
40. Inhibition of C3 with pegcetacoplan results in normalization of hemolysis markers in paroxysmal nocturnal hemoglobinuria.
Wong RSM; Pullon HWH; Amine I; Bogdanovic A; Deschatelets P; Francois CG; Ignatova K; Issaragrisil S; Niparuck P; Numbenjapon T; Roman E; Sathar J; Xu R; Al-Adhami M; Tan L; Tse E; Grossi FV
Ann Hematol; 2022 Sep; 101(9):1971-1986. PubMed ID: 35869170
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
